UA27137C2 - Спосіб одержаhhя вакциhи hа осhові живого атеhуйов - Google Patents

Спосіб одержаhhя вакциhи hа осhові живого атеhуйов

Info

Publication number
UA27137C2
UA27137C2 UA94129122A UA94129122A UA27137C2 UA 27137 C2 UA27137 C2 UA 27137C2 UA 94129122 A UA94129122 A UA 94129122A UA 94129122 A UA94129122 A UA 94129122A UA 27137 C2 UA27137 C2 UA 27137C2
Authority
UA
Ukraine
Prior art keywords
cells
lipid
cell
vzv
monolayer culture
Prior art date
Application number
UA94129122A
Other languages
English (en)
Russian (ru)
Inventor
Філіп Дж. Провост
Филип Дж. Провост
Девід Л. Крах
Девид Л. Крах
Пол А. Фрідман
Пол А. Фридман
Original Assignee
Мерк Енд Ко., Інк.
Мерк Энд Ко., Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/893,295 external-priority patent/US5360736A/en
Application filed by Мерк Енд Ко., Інк., Мерк Энд Ко., Инк. filed Critical Мерк Енд Ко., Інк.
Publication of UA27137C2 publication Critical patent/UA27137C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Спосіб отримання вакцини на основі живого атенуйованого вірусу вітряної віспи і оперізувального лишаю (VZV) штаму ОКА включає культивування чутливих до інфекції VZV диплоїдних клітин людини, інфікування вірусом, культивування інфікованих клітин, промивання і збір інфікованих клітин, руйнування їх із звільненням VZV і виділення цільового продукту. Клітини культивують в моношаровій культурі до стану суцільності в середовищі SRFE-2, що містить ліпід, вибраний з соєвого ліпіду в концентрації 0,02 - 0,4мг/мл, ліпіду з високим вмістом холестеролу з сироватки великої рогатої худоби, ліпіду EXCYTE I або ліпіду з низьким вмістом ендотоксину (VLE). За 24 - 96 годин до інфікування в середовище додають сахарозу, клітини інфікують вірусом при множинності інфекції від 1:25 до 1:625, потім інфіковані клітини культивують в SRFE-2, що не містить ліпіду, протягом 22 - 96 годин. Промивання клітин здійснюють в фізіологічному розчині.
UA94129122A 1992-06-04 1993-05-26 Спосіб одержаhhя вакциhи hа осhові живого атеhуйов UA27137C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89403992A 1992-06-04 1992-06-04
US07/893,295 US5360736A (en) 1992-06-04 1992-06-04 Process for attenuated varicella zoster virus vaccine production
PCT/US1993/004986 WO1993024616A1 (en) 1992-06-04 1993-05-26 Process for attenuated varicella zoster virus vaccine production

Publications (1)

Publication Number Publication Date
UA27137C2 true UA27137C2 (uk) 2000-02-28

Family

ID=27129046

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94129122A UA27137C2 (uk) 1992-06-04 1993-05-26 Спосіб одержаhhя вакциhи hа осhові живого атеhуйов

Country Status (28)

Country Link
US (1) US5607852A (uk)
EP (2) EP0573107B1 (uk)
JP (2) JP2599552B2 (uk)
KR (1) KR100350169B1 (uk)
CN (2) CN1069216C (uk)
AT (2) ATE206311T1 (uk)
AU (2) AU4392193A (uk)
BG (1) BG62176B1 (uk)
CA (1) CA2097019C (uk)
CZ (2) CZ289574B6 (uk)
DE (2) DE69334254D1 (uk)
DK (2) DK1097988T3 (uk)
ES (2) ES2317869T3 (uk)
FI (1) FI117758B (uk)
GR (1) GR3036812T3 (uk)
HU (1) HU220080B (uk)
MX (1) MX9303274A (uk)
NO (1) NO314068B1 (uk)
NZ (1) NZ253527A (uk)
PT (2) PT1097988E (uk)
RO (1) RO114906B1 (uk)
RS (1) RS50330B (uk)
RU (1) RU2126269C1 (uk)
SK (1) SK279387B6 (uk)
TW (1) TW349868B (uk)
UA (1) UA27137C2 (uk)
WO (1) WO1993024616A1 (uk)
YU (1) YU49210B (uk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029991A1 (en) * 1994-04-28 1995-11-09 Aviron A novel vzv gene, mutant vzv and immunogenic compositions
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
US6103529A (en) * 1996-10-10 2000-08-15 Life Technologies, Inc. Animal cell culture media comprising peptides derived from rice
GB9716611D0 (en) * 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
KR100378909B1 (ko) * 1998-03-18 2003-12-18 주식회사 엘지생명과학 사람세포주를이용한풍진백신의생산수율증대방법
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
WO1999057246A1 (en) * 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US20060286668A1 (en) * 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
JP3946045B2 (ja) * 2000-01-31 2007-07-18 財団法人阪大微生物病研究会 弱毒生水痘ワクチンの品質管理方法
CN1318580C (zh) * 2003-07-10 2007-05-30 北京科兴生物制品有限公司 可满足灭活疫苗生产的sars病毒规模化制备及灭活的方法
US7344839B2 (en) * 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
WO2008088410A2 (en) * 2006-10-17 2008-07-24 Medimmune, Llc Influencing viral lipid constituents
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
USRE47768E1 (en) 2008-08-11 2019-12-17 Sanofi Pasteur Biologics Llc Compositions and methods for the production of alpha-herpesviruses
CN101967466A (zh) 2009-07-28 2011-02-09 新泽西医学院 Orf7缺陷型水痘病毒株、含有该毒株的疫苗及其应用
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
CN103392001A (zh) * 2011-02-24 2013-11-13 牧岩生命工学研究所 新型水痘-带状疱疹病毒株以及使用所述毒株的水痘和带状疱疹病毒疫苗
WO2014062060A1 (en) * 2012-10-18 2014-04-24 Erasmus University Medical Center Rotterdam New method for producing high titer cell-free vzv vaccine virus
CN103074304B (zh) * 2013-01-28 2016-01-13 江苏健安生物科技有限公司 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法
US10350289B2 (en) 2013-09-05 2019-07-16 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
CN103740735B (zh) * 2013-12-31 2016-04-06 李越希 化学合成的HSV2病毒gC糖蛋白胞外区基因片段及其表达、应用
CN107206063B (zh) * 2014-12-01 2021-09-28 特兰斯吉恩股份有限公司 稳定的液体痘苗病毒制剂
RU2637093C1 (ru) * 2016-12-20 2017-11-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660565A (en) * 1968-04-17 1972-05-02 Wistar Inst Rubella vaccine and method
US3555149A (en) * 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5341202B2 (uk) * 1974-03-12 1978-11-01
US3961046A (en) * 1974-12-02 1976-06-01 American Cyanamid Company Mumps vaccine and preparation thereof
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
GB1481650A (en) * 1975-05-06 1977-08-03 Merck & Co Inc Chemical processes and products
JPS5251009A (en) * 1975-10-17 1977-04-23 Morinaga Milk Ind Co Ltd Method of producing drug for treating marrow leukemia
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
JPS5341202A (en) * 1976-09-28 1978-04-14 Fuji Photo Film Co Ltd Novel magnetic recording medium
JPS55147227A (en) * 1979-05-04 1980-11-17 Handai Biseibutsubiyou Kenkyukai Preparrtion of attenuated live mumps vaccine
US4252792A (en) * 1979-09-21 1981-02-24 Douglas Industries, Inc. Injectable rabies vaccine composition and method for preparing same
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS624370A (ja) * 1985-07-01 1987-01-10 Sharp Corp 半導体素子
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
WO1990003429A1 (en) * 1988-09-23 1990-04-05 Cetus Corporation Lipid microemulsions for culture media
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production

Also Published As

Publication number Publication date
CZ304594A3 (en) 1995-10-18
FI117758B (fi) 2007-02-15
EP0573107A2 (en) 1993-12-08
WO1993024616A1 (en) 1993-12-09
RO114906B1 (ro) 1999-08-30
NO944654L (no) 1995-02-03
CN1069216C (zh) 2001-08-08
DE69330850D1 (de) 2001-11-08
JPH06172215A (ja) 1994-06-21
CN1082923A (zh) 1994-03-02
PT573107E (pt) 2002-02-28
CZ289690B6 (cs) 2002-03-13
ES2161702T3 (es) 2001-12-16
BG62176B1 (bg) 1999-04-30
NO314068B1 (no) 2003-01-27
JP3156962B2 (ja) 2001-04-16
ATE206311T1 (de) 2001-10-15
KR100350169B1 (ko) 2004-05-20
FI945697A0 (fi) 1994-12-02
CA2097019C (en) 2007-07-24
AU4003693A (en) 1993-12-09
AU673167B2 (en) 1996-10-31
EP0573107A3 (en) 1995-04-26
HUT71863A (en) 1996-02-28
JPH09107958A (ja) 1997-04-28
AU4392193A (en) 1993-12-30
EP1097988A1 (en) 2001-05-09
DK0573107T3 (da) 2001-11-12
GR3036812T3 (en) 2002-01-31
YU7504A (sh) 2006-08-17
YU38893A (sh) 1996-02-19
US5607852A (en) 1997-03-04
BG99227A (bg) 1995-07-28
TW349868B (en) 1999-01-11
EP1097988B1 (en) 2008-12-31
MX9303274A (es) 1994-01-31
RS50330B (sr) 2009-11-10
NO944654D0 (no) 1994-12-02
DK1097988T3 (da) 2009-05-04
PT1097988E (pt) 2009-03-05
SK279387B6 (sk) 1998-10-07
CZ289574B6 (cs) 2002-02-13
NZ253527A (en) 1996-09-25
CN1307902A (zh) 2001-08-15
DE69330850T2 (de) 2002-04-11
FI945697A (fi) 1995-01-26
RU2126269C1 (ru) 1999-02-20
HU220080B (hu) 2001-10-28
EP0573107B1 (en) 2001-10-04
YU49210B (sh) 2004-09-03
JP2599552B2 (ja) 1997-04-09
SK148094A3 (en) 1995-07-11
CA2097019A1 (en) 1993-12-05
HU9403473D0 (en) 1995-02-28
ES2317869T3 (es) 2009-05-01
DE69334254D1 (de) 2009-02-12
ATE419332T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
UA27137C2 (uk) Спосіб одержаhhя вакциhи hа осhові живого атеhуйов
EP0474790B1 (en) Media for cell growth and method for making them
CN103422176A (zh) 人羊膜间充质干细胞库的构建方法
EP0067697B1 (en) Cell culture method
US4169761A (en) Process for the cultivation of viruses
Schmitt-Slomska et al. Group A Streptococcal L Forms I. Persistence Among Inoculated Mice
GB1464939A (en) Process for the production of interferon
US3935066A (en) Cell lines
JPS5754586A (en) Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it
PT71977B (en) Process for preparing hepatitis b surface antigen
Petkus et al. Pure spherules of Coccidioides immitis in continuous culture
AR005823A1 (es) Proceso para producir un virus varicela zoster libre de celulas
ADAM et al. Carbohydrate utilization by the soil amoeba Hartmannella castellanii
Brunk et al. Mycoparasitism of Dispira simplex and D. parvispora
McLean et al. Transmission of Northway and St. Louis encephalitis viruses by arctic mosquitoes
RU2053297C1 (ru) Способ культивирования вируса кори
McClary et al. Mitochondrial changes accompanying acriflavine-induced petite mutation in saccharomyces fragilis
JPS62163681A (ja) バベシアカニスの培養法と、その培養法を応用した抗原およびワクチンの製造法と、ピロプラスマ病用抗原およびワクチン
AU647031C (en) Media for cell growth and method for making them
Vivo CHARLES E. BLAND
Wu Studies on the Cultivation of Human Diploid Cells in Microcarrier Culture.
CZ281322B6 (cs) Heteroploidní buněčná linie fetální bovinní štítné žlázy FBTY
NO751303L (uk)